Imprinting and Cancer Group
Cancer Epigenetics and Biology Program (PEBC)
Bellvitge Institute for Biomedical Research (IDIBELL)
David Monk obtained his Ph.D. in 2001 from Imperial College London for studies describing cytogenetic aberration in Silver-Russell syndrome. This was followed by several post-doctoral projects characterizing epigenetic regulation in both mouse and humans, including a multicenter MRC funded position at MRC Harwell, Oxford, The Babraham Institute, Cambridge and Institute of Reproductive and Developmental Biology (IRDB), Imperial College London. Dr Monk initially held a lecturership at the Institute of Child Health (ICH), University College London before moving to the Cancer Epigenetic and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIEBLL) in Barcelona. His teams’ research is centered on understanding epigenetic mechanisms relevant to human diseases, focusing on the application of high-throughput genome technologies to analyze genomic imprinting. In particular, his studies have addressed the role of these epigenetically regulated transcripts in imprinting disorders, as well as in common morbidities, including fetal growth and cancer. Recently, his group has utilized methyl-seq to characterized methylation in human gametes and pre-implantation embryos, resulting in the identification of novel transient imprinted DMRs. These oocyte-derived maternally methylated regions surviving initial embryonic reprogramming and are found solely in the placenta. In addition to his research activities, Dr Monk is a working group leader for the European COST network for Human Congenital Imprinting Disorders (EUCID), specifically for coordinating research involving molecular biology. To date Dr. Monk has over 80 publications, 23 as senior researcher.